Mycobacterium species (M. spp.)

Mycobacterium species represent a genus of Gram-positive, aerobic, non-motile bacteria characterized by a unique, lipid-rich cell wall containing mycolic acids, which provides resistance to many standard antibiotics and environmental stressors [1]. This genus includes significant human pathogens, most notably Mycobacterium tuberculosis, the causative agent of tuberculosis, and Mycobacterium leprae, which causes leprosy [2]. From a pharmacological perspective, "Mycobacterium species" is a broad taxonomic category rather than a specific molecular target; however, it serves as the biological focus for a wide range of antimicrobial agents [3]. These drugs typically target essential bacterial components such as the cell wall synthesis machinery (e.g., InhA), RNA polymerase (RpoB), or ATP synthase (AtpE) [1,4]. The treatment of mycobacterial infections is often complicated by the bacteria's ability to enter a latent or persistent state and the rapid emergence of multi-drug resistant (MDR) strains [4]. Consequently, therapeutic regimens usually involve long-term combination therapy to ensure complete eradication and prevent the development of further resistance [3].

Other names

MycobacteriaAcid-fast bacilliAFBM. spp.

Drugs targeting Mycobacterium species act through several distinct mechanisms: inhibition of mycolic acid biosynthesis (e.g., isoniazid), inhibition of RNA synthesis by binding to the beta-subunit of RNA polymerase (e.g., rifampin), inhibition of arabinosyltransferase involved in cell wall synthesis (e.g., ethambutol), and inhibition of mycobacterial ATP synthase (e.g., bedaquiline) [1,3,4].